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                                                      TO   SHIRIDI   SANSTHAN                           

  
ABSTRACT 
Rheumatoid arthritis (RA) is a chronic systemic joint disease characterized by synovial 
inflammation, leading to destruction of cartilage and bone. Local recruitment of 
immune cells and defective apoptosis results in chronic inflammation with increased 
synovial citrullination and local hypoxia. Synovial inflammation by itself can promote 
destruction of bone by modulating the RANKL/RANK/OPG system. Recently it has 
been suggested that the two mechanisms are at least partly uncoupled. 
 
The aim of this thesis was to better understand pathogenic mechanisms responsible for 
inflammation and bone destruction and to study their modulation by effective anti-
rheumatic treatment. 
 
We demonstrated that T cells-resistance to apoptosis and protein citrullination are 
important features of the rheumatoid joints, potentially contributing to perpetuation of 
local inflammation. Intra-articular glucocorticoids fail to modulate synovial apoptosis 
but successfully decreased synovial citrullination both in vivo and in vitro. Modulation 
of synovial citrullination appears to be a drug specific effect rather than a consequence 
of decreased inflammation as far as methotrexate showed no effect when tested both in 
vivo and in vitro.  
 
We have identified synovial RANKL expression and hypoxia as two important factors 
mediating bone destruction independent of inflammation. First we showed that high 
levels of the RANKL/OPG ratio characterize early-untreated RA. Methotrexate 
treatment modulates synovial expression of RANKL and protects against future 
radiographic progression independent of the anti-inflammatory effect. The direct effect 
of methotrexate on bone metabolism was confirmed in vitro where dual mechanisms of 
action were identified consisting in both RANKL modulation and direct cellular effects 
on osteoclasts. Second we demonstrate that hypoxia modulates RANKL and OPG 
expression in osteoblasts through a HIF-2α mediated mechanism. Hypoxia promotes 
osteoclastogenesis and bone destruction acting both through up-regulation of the 
RANKL/OPG ratio and direct cellular effects on osteoclasts. The additive effect of 
hypoxia and inflammation observed in our in vitro osteoclastogenesis assays further 
support the idea that inflammation is not the only mechanism responsible for bone 
destruction in RA. 
 
In conclusion we have identified T cell resistance to apoptosis, citrullination, synovial 
expression of RANKL and hypoxia as important denominators of chronic inflammation 
and bone destruction in RA. Specific targeting of these molecular pathways might 
provide further insight in the complex pathogenesis of the disease and lead in the future 
to new therapeutic concepts. 
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1. History 
The term Rheumatoid arthritis (RA) was first coined by British Rheumatologist Dr. 
Alfred Baring Garrod in 1859. The foremost clinical description of RA was described 
from the studies in female population at Salpetiere hospital, Paris [1]. 
 
1.1 Epidemiology of RA 
The prevalence of RA varies from 0.5-1% population worldwide [2], at earlier ages in 
Native Americans and later in European countries [3, 4]. In north European countries 
like Sweden the prevalence rate is reported as 0.5-0.9% [5]. RA is more prevalent in 
women than men and the disease incidence increases with age up to 70 years [6]. 
 
1.2 Etiology  
Etiology of RA is not clearly known, but it is believed that RA results from the 
complex interaction between different risk factors including abnormal immune 
response, environmental factors, and genetic susceptibility. Genetic factors like HLA-
DR and the shared epitope has been reported as the major risk factor of RA [7]. Some 
other non HLA genetic factors such as polymorphism in genes PTPN22 and CTLA4 
have been recently reported as risk factors that might trigger the autoimmune disease 
[8]. Non genetic factors such as gender, smoking, socioeconomic status, infectious 
agents have long been studied as potential etiological factors of RA [5], with smoking 
being the most well established non-genetic risk factor.  
 
1.3. Background and description 
RA is a severe chronic autoimmune disease and is characterized by synovial joint 
inflammation leading to the destruction of articular cartilage and sub-chondral bone. 
Besides its main localization to the synovial joints, RA can also affect other tissues. 
Chronic persistent joint inflammation is due to both synovial accumulation and 
proliferation of inflammatory cells (macrophages and lymphocytes) and decreased 
apoptosis of resident cells in the synovium. This leads to excessive number of 
infiltrating inflammatory immune cells and production of pro-inflammatory cytokines 
that further amplify local inflammation and promote synovial hypertrophy with 
consecutive local hypoxia [9, 10].  
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2. Clinical manifestation       
RA clinically affects joints with local inflammation leading to swollen and tender joints 
and sometimes involvement of other tissues such as skin, lungs, heart and kidneys.  
 
2.1 Diagnosis and classification 
The diagnosis of RA is still today a clinical diagnosis based on a core set of clinical 
signs and symptoms and a series of laboratory findings. In order to homogenize study 
populations in clinical studies several sets of criteria for classification of RA emerged. 
In 1987 American College of Rheumatology (ACR) proposed criteria for classification 
of RA (table 1) [11].  
 
 
          Table.1. 1987  ACR criteria for rheumatoid arthritis 
 
     1 
 
     2 
 
 
 
     3 
 
     4 
 
 
     5 
 
 
     6 
 
     7 
 
Morning stiffness of the joints, lasting for 1 hour before maximal improvement. 
 
Involvement of arthritis atleast 3 joint areas soft tissue swelling or fluid retention. 
Possible areas are right or left proximal interphalangeal (PIP), metacarpophalangeal 
(MCP), wrist, elbow, knee, ankle and metatarsophalangeal (MTP) joints.  
 
Arthritis of hand joints, atleast 1 area swollen as mentioned above (criteria.2). 
 
Symmetric arthritis, simultaneous involvement of the same joint areas on both sides 
of the body. 
 
Presence of rheumatoid nodules, subcutaneous nodules over bony prominences or 
extensor surfaces or in juxta-articular regions. 
 
Presence of serum rheumatoid factor. 
 
Radiographic changes in hand and wrist which include erosions or unequivocal 
bony decalcification. 
 
The ACR guidelines included a classification criteria based on fully established 
manifestations of RA. However during last year’s these criteria proved to have low 
sensitivity for the classification of RA in more early stages of the disease. Recently, an 
updated and improved ACR and European League Against Rheumatism (EULAR) 
criteria was proposed in 2010 [12, 13]. The ACR-EULAR criteria (Table 2), evaluation 
are mainly based on the scores from four different categories aimed for classification of 
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RA. In order to classify as RA, a score of at least 5 in the presence of at least one 
swollen joint is needed.  
 
 
Table 2.         2010 ACR-EULAR classification criteria for rheumatoid arthritis 
Category.1(Joint involvement) 
a. 1 large joint (shoulders, elbow, hip, knee and ankle) 
b. 2-10 large joints 
c. 1-3 small joints (with or without involvement of large joints including 
MTP, PIP and wrists) 
d. 4-10 small joints (with or without involvement of large joints) 
e. >10 joints (at least one small joint) 
Score 
    0 
1 
2 
 
    3 
5 
 
Category.2 (Serology, at least 1 test result is needed for classification) 
a. Negative RF and negative ACPA 
b. Low-positive RF or low-positive ACPA 
c. High-positive RF or high-positive ACPA 
 
0 
2 
3 
 
 
Category.3 (Acute-phase reactants, at least 1 test result is needed for score       
                    classification) 
a. Normal CRP (C-reactive protein) and normal ESR (erythrocyte 
sedimentation rate-0) 
b. Abnormal CRP or normal ESR 1 
 
 
0 
 
1 
 
Category.4 (Duration of symptoms, self reported) 
a. <6 weeks 
b. ≥6 weeks 
 
0 
1 
 
 
2.2 RA evaluation and monitoring  
The assessment of a patient with RA is done by physical evaluation of tender and 
swollen joints, estimation  of systemic inflammation by measurements of acute phase 
reactants like erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), 
serum detection of rheumatoid factor (RF) and anti-citrullinated protein antibodies 
(ACPA) [14]. Global assessment of disease activity can be done by clinical composite 
scores such as the disease activity score 28 (DAS28). DAS score is commonly used to 
monitor the activity of disease and response to treatment in the clinical trials to define 
responders, moderate responders and non responders [15]. Monitoring of involved 
joints by X-rays, ultrasound and MRI are additional useful tools and may reveal the 
progression of disease at a more intimal level than clinical evaluation [16]. 
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2.3 Treatment 
Several treatment options are available in the management and control of RA. The aim 
of the treatment is to attain clinical remission or low disease activity as early as possible 
[17, 18]. In the absence of early and aggressive treatment, RA is chronic and severe in 
some cases. When left untreated the disease tend to develop to cause considerable 
morbidity with consecutive increased disability and mortality as compared to general 
population [19]. Currently, there are different classes of anti-rheumatic drugs available 
for RA treatment.  In 2008 ACR provided a set of recommendations for the use of 
different anti-rheumatic treatment options for RA and management of the disease [20] 
that to great extent are still valid today. Anti-rheumatic drugs include: non-steroidal 
anti-inflammatory drugs (NSAIDs), disease modifying anti-rheumatic drugs 
(DMARDs), glucocorticoiods (GCs) and biologicals. The clinical efficacy and mode of 
action of these drugs are addressed in detail in the section of therapeutic interventions. 
 
 
3. Current etiopathogenic hypothesis  
Complex immune-mediated inflammatory mechanisms are involved in the 
pathogenesis of RA. The initiation of disease is thought to be due to the interplay 
between genetic susceptibility and environmental factors leading to specific immune 
reactions. Evidences from twin studies show that genetic factors contribute 
approximately 60% for the disease pathogenesis [21]. In a twin gene study it is reported 
that the concordance rate of disease susceptibility is higher in monozygotic twins (12-
15%) than dizygotic twins (3-4%) [22]. It is well known that class II major 
histocompatibility complex (MHC) or Human Leukocyte Antigen (HLA) and shared 
epitope (SE) are major risk factor for RA [23]. Some other non HLA-genes have also 
been identified in the pathogenesis of RA but have a relatively lower risk susceptibility 
compared to individuals that carry the HLA-DR haplotype. These include a functional 
variant of intracellular protein PTPN22, transcriptional factor STAT4, and co-
stimulatory receptor CTLA-4 that may be involved in T and B cell activation [24, 25].  
 
It is believed that RA can initiate when specific interactions occur between these genes 
and environmental factors such as interaction between smoking and SE particularly in 
seropositive patients [26]. According to this hypothesis smoking is able to induce 
postranslational modification such as citrullination in the lungs of healthy smokers. In 
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the presence of right SE allele citrullinated proteins are more firmly and better 
presented as autoantigens on the surface of antigen-presenting cells. This further leads 
to immune activation of T cells and eventually B cells with production of specific 
antibodies (ACPA) in the serum of individuals that are yet not having any joint 
complaints and are still healthy. In this model a second hit leading to increased synovial 
citrullination over a certain threshold is needed, allowing circulating ACPA to localize 
to the joint and initiate local immune reactions. This in turn results in chronic 
inflammation due to increased cell recruitment and decreased cell clearance (defective 
apoptosis) leading to synovial hypertrophy with consecutive cartilage and bone 
destruction. 
 
Production of autoantibodies and in particular ACPA is a central event in the 
pathogenesis of RA. ACPA are highly specific for RA [27] and could be detected in the 
blood long before the onset of the disease. ACPA detection is currently used as a useful 
tool in the diagnosis and prognostic of RA. Their role in disease pathogenesis have 
recently been highlighted by their possibility to induce activation of monocytes through 
a Fcγ dependent mechanism [28] but also more interestingly through the potential 
direct interaction between these antibodies and citrullinated targets on cell surfaces [29, 
30]. Beside ACPA, rheumatoid factors (RF) are autoantibodies directed against Fc 
portion of IgG  and are commonly found in RA patients with somewhat lower 
specificity as compared to ACPA [27].  
 
 
4. Pathophysiology of synovium 
Joint synovial membrane is a soft tissue found between articular cavity and the capsule 
of the diarthrodial joints and synovium is the primary site of inflammation in RA.  
 
4.1 Healthy and RA synovium 
Normal synovium consists of two compartments the lining and sublining. The lining 
compartment is restricted to two to three cellular layers of macrophage-like or type A 
synoviocytes and fibroblast-like or type B synoviocytes in a loose extracellular matrix. 
The later is responsible for synthesis of collagen, fibronectin and hyaluronic acid that 
facilitate lubrication and maintenance of cartilage surface. The sublining layer contains 
vascular, fatty and connective tissue with sparsely dispersed mononuclear cells. In 
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inflammatory conditions such as RA, synovial lining layer becomes hyperplastic and 
thickened with more layers containing both cell types (A and B synoviocytes) leading 
to pannus formation that progresses to the adjacent joint bone [31]. In the sublining 
layer there is imported cell infiltration with activated macrophages, dendritic cells 
(DCs), natural killer (NK) cells, and T and B cells.  
 
Macrophages are the dominant cell type in RA synovitis and considered master 
regulators of the local inflammation. In addition differentiated CD4+ T cells of Th1 cell 
phenotype and CD8+ T cells might also be present diffuse or more grouped in  
aggregates in the sublining layer [32]. Accumulation of activated cells leads to 
secretion of proinflammatory cytokines and chemokines that further amplify local 
inflammation and promote neovascularization and synovial hypertrophy with 
consecutive local hypoxia [10, 33]. Synovial hyperplasia results in increased distance 
between blood vessels and synoviocytes, further increasing the demand for oxygen 
consumption from dysregulated blood vessels. Figure.1 represents the difference 
between normal (A) and inflamed RA (B) synovium.  
                 
    
 Figure 1. Microscopic image of haematoxylin (HTX) stained histology from normal (A) and RA (B)    
 synovial tissue. Arrow indicates infiltration of inflammatory cells. 
 
 
4.2 Synovial fluid (SF)  
The normal joint contains very low levels of SF needed for lubrication and function of 
the periarticular cartilage around the joint. In active RA, the volume of SF increases 
and is accompanied by an increase in inflammatory cells, cytokines and filtrates of 
plasma derived proteins within the joint space. Neutrophils are the dominant cell type 
in inflammatory SF. Excessive accumulation of immune cells in SF occur due to 
increased recruitment and resistance to apoptosis [9, 34] with high levels of 
chemotactic factors such as chemokines, leukotriene B4 and activated C5a complement 
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factors [35]. The lymphocyte population within the SF is mainly composed of CD8+ 
cells. Inflammatory SF contains activated cells, various inflammatory mediators and 
degradative enzymes that are responsible to damage cartilage and bone by 
chondrocytes and osteoclasts [36, 37]. Figure 2 illustrate the difference between normal 
synovial joint (A) and inflamed RA synovial joint (B). 
 
 
Figure 2. Schematic representation of synovial joint (A) normal synovium and (B) inflamed RA 
synovium (Adapted from Vibeke Strand et al. Nature Reviews 2007). 
 
 
4.3 Cellular and cytokine network in RA 
At the synovial level a complex network of sequential activated immune cells and pro-
inflammatory cytokines play an important role in initiation and propagation of chronic 
inflammation eventually leading to cartilage and bone destruction. 
 
4.3.1 Monocyte/Macrophages 
Monocytes are recruited from peripheral blood and migrate to tissues as macrophages. 
They are abundant in both synovial tissue and SF leading to synovial hyperplasia. 
Monocytes and macrophages are phagocytic cells upon activation by inflammatory 
stimuli through Toll like receptors (TLRs) and serve as link for both innate and 
adaptive immune functions [38]. These cells express different lineage markers like 
CD14, CD68, and CD163 and activation phenotypic marker like MHC class II surface 
molecule. The monocyte-macrophage system is the major source of pro-inflammatory 
cytokine production [39]. Some of the important secreted cytokines include TNFα, IL-
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1, IL-6, IL-12, IL-15, IL-23, GM-CSF and chemokines with both autocrine and 
paracrine actions [40]. Anti-inflammatory cytokines such as IL-10, TGF-β and IL-1Ra, 
are also present in the rheumatoid joint but not able to suppress inflammation 
presumably overwhelmed by the amount of pro-inflammatory local events. Monocytes 
can also act as osteoclast precursor cells, which upon stimulation with macrophage 
colony stimulating factor (M-CSF) express RANK receptor and induce 
osteoclastogenesis in the presence of osteoclast differentiation factor RANKL [41, 42]. 
Pro-inflammatory cytokines like IL-1 and TNFα have been reported to induce 
osteoclastogenesis from monocytes precursors with consecutive bone resorption in the 
presence of permissive levels of RANKL [43, 44].  
 
4.3.2 Fibroblasts 
Fibroblasts-like synoviocytes (FLS) are found in the lining and in the sublining layer of 
the synovitis. FLS from RA patients display a unique phenotype [45]. FLS are non-
phagocytic, non immune cells, able to secrete a variety of cytokines and exhibiting 
some features similar to transformed cell features [45]. FLS are an important source of 
cytokines and chemokines such as IL-6, IL-15, IL-8, CCL5 and CXCL1 that actively 
contribute to recruitment of immune cells (neutrophils, T and B cells) to the inflamed 
synovium [46]. In RA, FLS are the major source of proteolytic enzymes like 
cathepsins, matrix metalloproteinases (MMPs) and acid metabolites that directly invade 
tissue matrix and destroy the cartilage [47]. Upon activation FLS can express RANKL 
that might contribute to the local induction of osteoclast and bone destruction [48].  
 
4.3.3 Lymphocytes 
Lymphocytes include T-cells, B-cells and Natural killer cells (NK) and are present 
mainly in the sublining layer rather than lining layer of the synovial tissue. Synovial T 
cells of RA express a phenotype suggesting chronic immune activation, but they are 
anergic and resistant to apoptosis [49]. They are present either as aggregates sometimes 
resembling germinal centers or diffusely widespread in the synovium. They express 
CD3 and can be further subdivided in CD4+ T-helper (Th), CD4+T-regulatory cells (T-
regs), or CD8+ cytotoxic T cell (Tc-cell). CD4+ Th cells are the dominant subtype of T 
cells in the inflamed synovium.  Depending on the cytokines present in a specific 
environment Th cells further differentiate into Th1, Th2 and Th17 phenotypes [49]. 
CD8+ Tc cells are cytotoxic or killer cells that can bind to MHC class I molecule. They 
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are present in the inflamed joint but thought to have a secondary role in disease 
pathogenesis.  
 
B-cells and plasma cells are mainly seen in the sublining layer of the synovium and 
reside together with T cell population. B-cells are essential components of humoral 
immunity, and are characterized by B-cell receptor (BCR) expression and are able to 
bind directly to antigen to activate immune response. Their contribution in RA 
pathogenesis is by production of autoantibodies like RF and ACPA [50-52]. Synovial B 
cells secrete cytokines like TNFα, IL-2, IL-4, IL-6 and IL-12 contributing to local 
inflammation by activating dendritic cells and T cells [53, 54]. 
 
NK cells are CD3 negative, CD16 or CD56+ and can be identified in the SF of 
established RA. Their activity and cytotoxicity is enhanced by IL-2 and IL-15 
cytokines [55, 56]. Besides cytotoxicity NK cells produce cytokines like IFN-γ, TNFα, 
IL-4, IL-13, and IL-10 [57]. Recent studies reported that NK cells in the SF could 
trigger the differentiation of osteoclast and bone destruction in arthritis when co-
cultured with monocytes through a process dependent on RANKL and M-CSF 
induction [58].  
 
4.3.4 Neutrophils 
Neutrophils are the most predominant cell type and constitute about 70% of the cell 
population in the inflamed SF and to a lesser extent in the synovial tissues of RA. [35]. 
Upon migration to specific sites of inflammation they release proteases and oxygen free 
radicals leading to the destruction of cartilage and other tissues [35, 59]. Neutrophils 
regulate both the innate and adaptive immunity and their function is mediated through 
TLR activation [60, 61] and secretion of cytokines like IL-1α and IL-1β in RA [62]. It 
is reported that neutrophils can secrete cytokines like BAFF and APRIL which are 
crucial for the cell survival, maturation and differentiation of B cells [63, 64]. In 
addition, RA SF neutrophils can induce osteoclast formation and bone resorption 
through the upregulation of functionally active membrane bound RANKL [65].  
 
4.3.5 Dendritic cells (DCs) 
DCs present in the synovial sublining layer are mostly located around the lymphoid 
aggregates, and constitute about 10% of total cell population in SF. They are present in 
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the blood stream in an immature state, and upon activation they migrate to the lymph 
nodes where they interact with T and B cells and act as the mediators for innate and 
adaptive immune system. Activated and mature DCs express high levels of HLA-DR 
and are referred as professional antigen-presenting cells. They express CD83, a 
transmembrane glycoprotein of Ig superfamily and are expressed on cultured, follicular 
and circulating DCs. They also express adhesion molecules CD11a, CD11c, CD54 and 
co-stimulatory molecules like CD80 that are upregulated during DC activation. DCs are 
responsible for the activation and perpetuation of immune response for RA 
pathogenesis and breaking of self-tolerance through the antigen-presentation to 
autoreactive T cells [66, 67]. In RA, mature DCs secrete pro-inflammatory cytokines 
IL-1, IL-6 and TNFα, and their production in DCs is mainly influenced by Fcγ receptor 
dependent pathway [68]. DCs are derived from monocytes in the presence of IL-4 and 
GM-CSF, and further could differentiate into bone resorbing cells in the presence of M-
CSF and RANKL [69]. 
 
4.3.6 Endothelial cells 
Endothelial cells expressing CD31 and CD34 and play an important role in RA. 
Endothelial cells are active participants in the inflammatory process in recruiting 
leukocytes and other immune cells.  It has been reported that the inflammatory 
cytokines IL-1 and TNFα upregulate the expression of endothelial cell adhesion 
molecules ICAM-1, VCAM-1 and E-selectin to recruit leukocyte migration into the 
synovial joint [70]. Neovascularization is a major feature of the inflamed synovial 
tissue driven by the hypoxic local environment through up regulation of vascular 
endothelial growth factor (VEGF) a potent angiogenic stimulator [71].  
 
 
5. Pathogenic mechanisms of inflammation and bone destruction in 
RA 
Once initiated, synovial inflammation is maintained and propagated through 
contribution of several distinct pathogenic pathways such as increased recruitment of 
immune cells, defective apoptosis of synovial resident cells, up-regulation of synovial 
citrullination, profound hypoxia and up-regulation of the RANKL/RANK/OPG 
pathway. 
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5.1 Synovial inflammation and apoptosis  
Excessive inflammatory cells infiltration in the synovial tissue results from both 
increased cell recruitment and local synovial defective cell death mechanisms [9, 34]. 
Apoptosis is a physiological process of programmed cell death, and is a highly 
conserved multi-step process. Apoptosis is distinguishable from necrosis by formation 
of apoptotic cell bodies that are cleared by macrophages without extracellular release of 
intracellular matrix and therefore without concomitant inflammation [72, 73]. Deficient 
apoptotic machinery has been implicated in the pathogenesis of a wide range of disease. 
 
Apoptosis can be initiated by two major common pathways called extrinsic and 
intrinsic pathways. The extrinsic apoptotic pathway leads to recruitment of the 
intracellular adaptor protein FADD following interaction between death ligands (FasL 
and TNFα) and death receptors (Fas and TNF receptor) to activate pro-caspase 8 [74]. 
Active caspase 8 initiates a cascade activation of several others caspases leading to 
effector caspase 3 activation [75]. Among cell death receptor ligands TNF has a dual 
effect. Dependent on the local tissue environment TNF might either initiate the 
extrinsic apoptotic pathway or induce NF-ĸB activation that in turn inhibits the 
apoptotic machinery. The second intrinsic apoptosis pathway is initiated by various 
extracellular stimuli such as UV-irradiation and depletion of growth factors, leading to 
cytocrome c release from mitochondria with recruitment of Apaf-1 and pro-caspase 9 
to form the apoptosome. This results in activation of caspase 9 and subsequently 
activation of caspase 3.  Smac/DIABLO acts as antagonist to inhibit the inhibitor of 
apoptosis protein IAP and further allow activation of caspase 3. Both extrinsic and 
intrinsic pathways converge with the activation of caspase 3 resulting in subsequent 
induction of apoptosis. Caspases 3 initiate DNA fragmentation leading to the 
characteristic appearance of an apoptotic cell with cell shrinkage, membrane blebbing, 
chromatin condensation and nuclear fragmentation [72]. The extrinsic pathway is 
blocked by FLIP, while the intrinsic pathway associated bcl-2 family is the main 
regulator of mitochondrial pathway. In which the bcl-2 member of the family being 
anti-apoptotic while bax members are pro-apoptotic. Figure 3 illustrate the two 
apoptotic pathways. 
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Figure 3. Schematic representation of extrinsic and intrinsic apoptotic pathways (Hongtao Liu et al, 
Current Opinion in Pharmacology 2003). 
 
[Abbreviations: Fas ligand (FasL), Tumor necrosis factor alpha (TNFα), Fas-associated death domain 
(FADD), FLICE inhibitory protein (FLIP), Bcl-2-associated X protein (BAX), Bcl-2 homologous 
antagonist killer (BAK), TNF receptor associated factor (TRAF), Nuclear Factor kappa B (NF-ĸB), 
activator protein 1 (AP1), Phosphotidylinositol-3 OH kinase (PI3K), protein kinase B (PKB), B-cell 
leukemia lymphoma-2 (Bcl-2), B-cell leukemia XL (Bcl-xl), inhibitor of apoptosis family proteins (IAP), 
second mitochondria-derived activator of caspases (Smac), direct IAP binding protein with low pI 
(DIABLO), apoptosis protease activating factor 1 (Apaf-1)]. 
 
 
A variety of methods could be used to analyze apoptosis in tissues and/or cell cultures. 
TUNEL technique can be used to label apoptotic fragments of DNA and electron 
microscopy is used to identify the apoptotic morphology of a cell [76, 77]. Staining 
with annexin V is used to detect the translocation of phosphatidylserine molecule from 
the cytoplasm to the cell surface. In addition, antibodies have been developed 
recognizing only active but not inactive uncleaved caspases that can be used to detect 
intracellular active caspases by immunostainings. DNA laddering, ELISA based 
detection of caspase activity, detection of the mitochondrial membrane potential are 
other methods that can be used.  
 
In RA synovial tissue, low levels of apoptosis (1-3%) have been reported. It is believed 
today that high synovial expression of anti-apoptotic factors is responsible for this in 
macrophages for examples resistance to apoptosis is due to high expression of 
occurring FLIP associated with low levels of apoptosis in RA synovium [78, 79]. Also, 
synovial NF-ĸB activation in the synovium [80] contribute to further inhibition of 
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macrophage apoptosis [81]. Activated synovial fibroblasts when co-cultured with B 
cells induce lymphocyte resistance to apoptosis in a cell contact and adhesion molecule 
dependent mechanism [82]. Enhanced synovial expression of anti-apoptotic molecules 
Bcl-2 and Bcl-xl, but not pro-apoptotic molecules in RA further contribute to low levels 
of synovial apoptosis [83]. Synovial RA T cells are also resistant to apoptosis [49, 84]. 
Chronic exposure to TNFα, IL-2 receptor γ chain signaling cytokines and inhibitory 
signals received through interaction with stromal cells have been all implicated in 
generating the apoptotic resistant phenotype of synovial T cells [85]. Infiltrating T cells 
in the synovium express also high levels of the anti-apoptotic molecules Bc1-2 and Bcl-
xl [84]. 
 
 
5.2 Synovial inflammation and citrullination 
Citrullination or deimination is a process of post translational modification of charged 
peptidyl arginine to neutral peptidyl citrulline by peptidylarginine deiminase (PAD) in 
the presence of calcium [86] (Figure 4). There are five different classes of PAD 
enzymes identified in humans (PAD-1, PAD-2, PAD-3, PAD-4 and PAD-6) that are 
expressed in variety of tissues. PAD-2 and PAD-4 are expressed in RA synovium and 
SF cells [87, 88] Protein citrullination is dependent on the activity of PAD enzymes, 
which is regulated by calcium concentrations.  
 
Citrullination occurs normally in the hair follicle as an important process for 
maintaining the structure of the hair fiber [89]. Also, citrullination occurs 
physiologically in keratin and fillagrin in the cornified layers of epidermis [90] and in 
the central nervous system [91]. Citrullination also regulates histone arginine 
methylation at the multiple arginine sites in the histone N-terminal tails [92]. In 
multiple sclerosis (MS) abundant expression of citrullinated proteins in the brain 
increases risk of demyelination and subsequent exposure of immunodominant epitopes 
[93]. Chronic inflammation also associates with excessive citrullination [94]. In RA 
citrullination of several synovial tissue proteins have been reported including 
fibrinogen, vimentin and α-enolase [95-97]. Increased citrullination is not a specific 
trait of the rheumatoid synovium but rather general phenomena in the context of 
inflammation and occurs in a large array of inflammatory tissues both synovial and 
extra synovial tissues [98, 99]. 
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 Figure 4. Citrullination occur due to the conversion of aminoacid arginine to citrulline by PAD enzyme 
 in the presence of calicium (Klareskog et al, Annu Rev Immunol. 2008).          
 
 
5.3 Synovial inflammation and the RANKL/RANK/OPG system 
In RA, it has been postulated that bone destruction occurs as a direct consequence of 
inflammation. This has been recently challenged by the observation that bone 
destruction can occur in RA despite clinical remission [100, 101], while specific anti- 
rheumatic drugs and/or combination of drugs might protect against destruction even in 
the absence of clinical remission [102, 103]. Taken together these findings suggest that 
inflammation and bone destruction are at least partially uncoupled in RA. Bone 
destruction is a dynamic process and homeostasis of bone metabolism is maintained by 
balance between bone matrix restoration and resorption [104, 105]. Bone is a rigid and 
hard tissue that is constantly being reshaped by osteoblasts and osteoclasts, in which 
osteoblasts are responsible for the production and mineralization of bone matrix to 
synthesis bone, whereas osteoclasts are multinucleated giant cells responsible for the 
breakdown of bone by demineralization and subsequent transfer of calcium from bone 
fluid to the blood. In a healthy individual the function of these two cells maintain the 
normal physiological bone metabolism and architecture. The underlying key molecular 
cascade that is responsible for bone resorption and restoration is mediated through 
RANKL/OPG/RANK pathway system [106, 107].  
 
RANKL is also known as osteoclast differentiation factor (ODF), Osteoprotegerin 
ligand (OPGL), and TNF related activation-induced cytokine (TRANCE) [108] and is a 
member of the tumor necrosis factor family of transmembrane proteins. Three RANKL 
isoforms are currently identified where RANKL1 and 2 induces multinucleated 
osteoclastas while RANKL3 lacking the intracellular and transmembrane domains has 
no effect on osteoclasts when expressed alone [109]. RANKL is expressed by activated 
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T-cells, fibroblasts and stromal/osteoblastic lineage cells. OPG is mainly expressed by 
endothelial cells, osteoblasts and fibroblasts [110, 111]. Receptor activator NF-kappa B 
(RANK) is a membrane receptor protein that is expressed mainly by osteoclast 
precursor cells in the synovial joint and is an important factor in the regulation of 
osteoclastogenesis [112].  
RANKL effects are counteracted by Osteoprotegerin (OPG), a secretory active decoy 
receptor protein also known as Osteoclastogenesis inhibitory factor (OCIF), able to 
bind directly to both membrane bound and soluble form of RANKL [113]. In the 
presence of macrophage colony stimulating factor (M-CSF), RANKL acts as a 
regulatory factor for fusion, activation and differentiation of multinucleated mature 
osteoclast to promote bone resorption [114]. M-CSF is a homodimeric glycoprotein 
promoting differentiation of monocytes and osteoclast survival [115, 116]. The binding 
of RANKL to RANK receptor induces the trimerization of RANK and TRAF6 adaptor 
molecule, leading to activation of mitogen activated kinase (MAPK) and NF-ĸB 
pathway [117]. Activation of RANK receptor also induces the transcriptional factor 
called activator protein 1 (AP1) through cellular proto-oncogene cFOS induction [118]. 
RANKL acts as a major stimulator of the Nuclear factor of activated T cells 
cytoplasmic 1 (NFATc1) through TRAF6, NF-ĸB and cFOS pathway needed for 
terminal differentiation of osteoclasts [119]. NFATc1 regulates expression of a set of 
genes essentials for osteoclasts such as tartrate resistant acid phosphatase (TRAP), 
cathepsin K, calcitonin, osteoclast associated receptor (OSCAR) and β3-integrin [119].  
RANKL is considered to be the main link between immune mediated inflammation and 
bone metabolism [120]. Activated macrophages produce pro-inflammatory cytokines 
such as TNFα, IL-1 and IL6, all able to enhance RANKL mediated osteoclastogenesis 
[121]. TNFα and IL-1 also up-regulate RANKL expression in osteoblast cells [122]. 
Activated T cells present at the site of synovial inflammation are able to secrete IL-17 a 
potent inducer of osteoclastogenesis [123]. This effect is counteracted by T cells 
producing IFN-γ that can inhibit osteoclasts occur through RANKL signaling and 
down-regulation of TRAF6. The balance between IL-17 and INF-γ secretion 
determines the ability of the T cell to mediate osteoclastogenesis [123, 124]. It has also 
been shown that in adjuvant arthritis model, activated T cells are able to induce 
osteoclast differentiation directly through RANKL expression [125]. Interaction 
between RANKL and RANK has a regulatory function on DC activation through T 
cell-DC interaction [126]. Moreover, RANKL is an important differentiation factor for 
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cell migration and tissue-specific metastatic behavior of cancer cells and may function 
as a chemokine [127]. Figure 5 schematic representation of the current view on the link 
between inflammation and bone destruction and the role of RNAKL pathway in 
destructive arthritis. 
                 
Figure 5. Bone metabolism is exemplified by perfect balance between RANKL and OPG ratio. During 
inflammatory conditions and other physiological disorders leads to the excessive RANKL production 
which results in bone destruction. 
 
 
5.4 Synovial inflammation and hypoxia  
Local synovial accumulation of immune cells and pro-inflammatory cytokines 
promotes synovial hypertrophy and results in very low levels of oxygen tension with 
profound local hypoxia. These changes promote tissue angiogenesis resulting in new 
vessels of bad quality further contributing to decreased oxygen supply into the tissues. 
An inflamed joint is characterized by oxygen levels ranging from 2 to 4% (18 to 33 
mmHg), as compared to 9 to 12% (69 to 89 mmHg) in patients without RA [128, 129]. 
The hypoxic environment of the chronically inflamed joint has been also confirmed by 
synovial identification of different traits associated with the typical anaerobic 
metabolism with raised carbon dioxide, lactate, and acetate levels, with a consecutive 
decreased synovial pH level [10]. With the aid of NMR spectroscopy technique, low 
molecular weight metabolites consistent with hypoxia were identified in the inflamed 
joints environment [130]. Visualization of tissue hypoxia can be done using intravital 
pimonidazole staining or immunohistochemical detection of HIF [131, 132]. The 
central role of hypoxia in the pathogenesis of inflammatory arthritis has been 
demonstrated when HIF deletion in macrophage and neutrophils resulted in complete 
protection from arthritis induction [133]. Furthermore, therapeutic inhibition of HIF-1α 
nuclear translocation suppresses transcription of the VEGF and ameliorates adjuvant-
induced arthritis in rats [134]. Both HIF-1 and 2α are expressed in the RA in synovial 
lining layer and stromal cells [135].   
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In order to adapt to hypoxia a transcription factor HIF-α (hypoxia inducible factor 
alpha) is activated, that in turn activates a large set of genes responsible for cell survival 
despite low levels of oxygen. HIF is a heterodimeric transcription factor consists of β-
subunit and an oxygen regulated α-subunit. HIFα and β subunits dimerize and then 
translocate to nucleus and bind to DNA.  HIF-α stability and function is maintained by 
oxygen-dependent prolyl hydroxylase domain-containing proteins (PHD), targeting 
critical proline residues. As a consequence, HIF-α subunit becomes recognizable by the 
von Hippel Lindau (vHL) tumour suppressor protein/E3 ubiquitin ligase, leading to 
polyubiquitination and proteosomal degradation [136, 137]. HIF-α subunit also 
contains two transactivation amino-terminal and carboxyl-terminal domains (C-TAD). 
HIF-α C-TAD interacts with two transcriptional co-activators called Creb binding 
protein (CBP) and p300 for transcriptional activation [138]. Under hypoxic conditions 
HIF-α subunit gets stabilized and translocate to the nucleus, and dimerize with β-
subunit by basic helix-loop-helix and Per-Arnt-Sim domains and binds to the hypoxia-
responsive elements (HRE) to regulate transcription of downstream target genes 
(Figure 6). Three different HIF isoforms have been reported. HIF-1α is ubiquitously 
expressed in all tissues.  HIF-2α expression is more tissue restricted and mainly present 
in high-vascularized tissues such as lung, kidney and liver. HIF-3α is expressed only in 
kidney, brain, heart and thymus [139, 140]. It is believed that HIF-1α and HIF-2α 
encounter similar responses to hypoxia due to their structural similarities. However, 
HIF-1α is rapidly and transiently expressed during hypoxia, whereas HIF-2α expression 
becomes steady after more prolonged hypoxia exposure [141]. 
 
                 
 
 
 
                
                                                               
                           
 
 
                  
 
Figure 6. Schematic illustration of oxygen dependent HIF-α regulation of downstream target genes.  
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Apart major regulation by oxygen levels, several other stimuli such as pro-
inflammatory cytokines modulate HIF expression under normoxic conditions. TNFα 
mimics hypoxia by inducing HIF-1α expression and stability via NF-ĸB pathway [142]. 
The intracellular IKKb kinase essential for NF-ĸB activation is also a critical 
transcriptional activator of HIF-1α in macrophages responding to bacterial infection 
[143]. Hypoxia induced neutrophil survival is mediated by HIF-1α dependent NF-ĸB 
activity [144].  
 
6. Therapeutic targeting of synovial inflammation 
Synovial inflammation is targeted today by several distinct drug classes such as 
NSAID, glucocorticoids, disease modifying anti rheumatic drugs (with methotrexate 
being the most frequently used) and more newer biological drugs. While biologicals 
have developed as a direct consequence of the better understanding of the molecular 
mechanisms responsible for synovial inflammation, older drugs such as DMARDs and 
glucocorticoids were initially used empirically based on the effects of these drugs on 
other disease entities.  Consequently less is known on the exact mechanism of action of 
these drugs despite their long use in clinical practice. A better understanding of their 
clinical and molecular effect is a pre-requisite for a better use of the therapeutic arsenal 
available today and future development of new therapeutic strategies. We studied 
therefore not only new potential pathogenic mechanisms important for development of 
synovial inflammation but also how different distinct anti-rheumatic drugs modulates 
these processes. We focused our studies on the mechanisms of action of methotrexate 
and intra-articular glucocorticoids.  
 
6.1 Anti-inflammatory effects of methotrexate (MTX) in RA 
MTX is a folate antagonist that acts by inhibiting dihydrofolate reductase and blocks 
the conversion of dihydrofolate to tetrahydrofolate in the folic acid metabolism, 
essential for purine and pyrimidine synthesis.  MTX enters the cell and exert its effect 
through the reduced folate carrier (RFC1) [145]. After absorption MTX is converted 
into 7-hydroxymethotrexate in the liver and shows low to medium protein binding and 
high tissue distribution [146]. After administration MTX diminishes its presence in 24 
hours and its half-life is 6 to 8 hours. MTX and hydroxymethotrexate are metabolized 
to polyglutamate derivatives (MTXGlu) stored in tissues as well as in liver and 
erythrocytes for long time [147]. MTXGlu inhibit 5-aminoimidazole-4-
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carboxyamideribonucleotide (AICAR) transformylase leading to accumulation of 
intracellular AICAR and AICAR metabolites, which in turn directly inhibit adenosine 
and AMP deaminases. As a consequence adenosine and adenine nucleotides 
accumulate intracellulary [146].  In parallel an increase in the extracellular adenosine 
has also been reported but the exact mechanism leading from intra to extra-cellular 
accumulation of adenosine is still incompletely understood. Adenosine is a purine 
nucleoside which can binds to adenosine receptors such as A1, A2a, A2b and A3 
present on different cells and exerts either immunostimulatory or immunosupressive 
effects. It has been shown that adenosine acts as an endogenous regulator of innate 
immunity and activation of A1-receptor stimulate neutrophils, while activation of A2a 
and A3 receptor has immunosuppressive effects [148]. It is believed that MTX partly 
exerts its anti-inflammatory effects through an A2a or A3 receptor mediated effects 
[149]. 
 
Other suggested mechanisms of action for MTX are suppression of T cell proliferation, 
apoptosis induction [150, 151] and modulation of cytokine production including IL-4, 
IL-6, IL-13, TNFα, IFN- γ and GM-CSF [152-154]. MTX also inhibits the cell contact-
dependent interaction between fibroblast and T cells [155]. Other studies have 
demonstrated that MTX decreases IgG FcγR expression on monocytes and thus prevent 
activation of immune complex formation [156].  MTX also has an inhibitory effect on 
cellular adhesion molecules including E-selectin and ICAM-1, which result in the 
reduction of tissue cellular recruitment [157, 158].  
 
6.2 Anti-inflammatory effects of intra-articular glucocorticoids (GCs) 
in RA 
GCs are potent anti-inflammatory drugs, widely used as an adjuvant for the treatment 
of RA to dampen the inflammation in accessible joints[159]. Among intra-articular 
GCs, triamcinolone hexacetonide and methylprednisolone acetate are the most 
commonly used. Treatment with intra-articular GCs significantly reduces synovial 
infiltration of T-cells [160] Fcγ receptor expression [161] and production of pro-
inflamatory cytokines and adhesion molecules such as TNFα, IL-1β, HMGB-1, ICAM-
1 and VEGF [33]. Treatment with intra-articular GCs appears not only to modulate 
synovial inflammation but possibly also cartilage and bone destruction as demonstrated 
by decreased serum levels of markers for cartilage turnover [162] and decreased 
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synovial RANKL expression following intra-articular administration of GC [160]. In 
vitro exposure of T cells to GCs induces apoptosis, primarily mediated through the 
mitochondrial cell death pathway [163]. 
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7. GENERAL AIM OF THESIS 
The general aim of the current thesis is to identify and characterize new molecular 
mechanisms responsible for synovial inflammation and bone destruction in RA. 
 
7.1. Specific aims of the thesis 
 
• To characterize sensitivity of RA synovial T cells to GC-induced apoptosis in 
vivo and in vitro.  
• To characterize synovial citrullination patterns in relation to local 
inflammation and anti-rheumatic treatment in RA. 
• To characterize synovial expression of bone remodeling markers (RANKL, 
RANK and OPG) in early untreated RA and their modulation by 
methotrexate.  
• To study the interaction between inflammation and hypoxia in promoting 
inflammation associated bone loss in RA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22 
8. RESULTS AND DISCUSSION 
The present work focused on the investigation of alternative molecular mechanisms 
that might be relevant for and contribute to perpetuation of chronic synovial 
inflammation in RA.  
 
Low levels of apoptosis in RA synovial T cell population is independent of local 
levels of inflammation. 
Others and we have previously showed that low levels of synovial apoptosis 
characterize RA monocyte/macrophage population [79, 164]. We aimed in the first 
study (paper 1) to extend our findings to characterize synovial T cells apoptosis. We 
first confirmed low levels of synovial RA apoptosis evaluated as both TUNEL positive 
(5.2±1.3, mean±SEM) and active caspase 3 positive (3±0.4, mean±SEM) cells.  
Furthermore, we identify the synovial CD3+ cells as a highly apoptosis-resistant 
subpopulation, with less than 2% of them showing morphological signs of apoptosis. 
Administration of intra-articular GC failed to induce synovial apoptosis despite a 
general reduction of the CD3 subpopulation and good clinical response in all treated 
patients as evaluated by arthroscopy (figure 7).  
 
 Figure 7. Knee arthroscopic images of RA joint before (A) and after (B) intra-articular GCs. 
  
Also confirming our previous data no changes in the number of macrophages evaluated 
as both CD68 and CD163+ cells were observed following intra-articular administration 
of GC (figure 8). 
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Figure 8. Synovial biopsy tissues showing surface markers CD68 (A) and CD163 (B) before and after 
intra-articular GC treatment. 
 
Taken together our biopsy data suggest that in vivo intra-articular GC reduces synovial 
inflammation through reduction of the number of CD3+ lymphocytes without 
influencing the monocyte/macrophage population. The mechanism responsible for the 
reduction of the CD3+ cell number is decrease local recruitment [33] rather than 
increased apoptosis.  
 
RA apoptosis-resistant T cell phenotype is due to soluble factor(s) cross talk 
between monocytes and lymphocytes. 
To further investigate the mechanisms rendering synovial T cells resistant to apoptosis, 
we first examined the capacity of different synthetic glucocorticoid preparations to 
mediate apoptosis of T cells derived from the SF of RA patients.  None of the 
investigated compounds were able to induce CD3+ cell apoptosis when SF derived 
mononuclear cells containing a mixture of both lymphocytes and monocytes were 
cultured together. A positive control for apoptosis induction in our cell systems showed 
that GC were able to induce apoptosis of CD3+ cells derived from the SF of patients 
with another type of inflammatory joint disease (psoriasis disease). Separate cell culture 
of RA-derived isolated CD3+ cells in the presence of GC resulted in apoptosis 
induction suggesting that interaction between monocytes and lymphocytes is essential 
for maintaining an apoptosis-resistant phenotype in RA lymphocytes. Interestingly, 
when isolated monocytes and lymphocytes were co-cultured in transwell experiments, 
allowing inter-cellular communication via soluble factors but not physical cell-cell 
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contact, CD3+ cells were rendered again resistant to GC mediated apoptosis.  We 
conclude that T cell resistance to apoptosis seems to be an RA specific trait and 
mediated through the soluble cross talk with monocytes. The exact mediator(s) remains 
to be determined.  
 
Synovial citrullination is readily detected in the RA synovium and dependent on 
local inflammation. 
Others and we have previously shown that citrullinaton occurs in different contexts of 
inflammation and in a variety of tissues [98]. In (paper 2) we aimed to further 
characterize the pattern of synovial citrulliantion in relation to local inflammation. At 
the time of this study was initiated technical difficulties in detecting the presence of 
citrullinated protiens in tissues and Western blots appeared, due to the disappearance 
form the market of the well validated modification method originally described by 
Senshu [165]. To circumvent this we chose to use a mouse IgM monoclonal antibody 
(F95) raised against a deca-citrullinated peptide that we have previously validated by 
comparison with the Senshu method [166]. As expected citrullination was readily 
detected in the inflamed RA synovium and virtual absent from the healthy non-
inflamed synovial tissue. We further analyzed expression patterns of PAD-2 and PAD-
4 the only peptidyl deiminases present in synovial tissue. PAD-2 and PAD-4 expression 
was detected in all baseline RA samples and a vast majority of the healthy synovial 
biopsies. Correlations between semi-quantitative scores for synovial citrullination and 
PAD enzymes expression on one hand and inflammation on the other hand further 
confirmed the closed interrelationship between the two phenomena. 
 
Synovial citrullination is specifically down regulated by GC but not MTX. 
Following our observations showing a high degree of correlation between synovial 
citrullination and inflammation we hypothesized that successful anti-rheumatic 
treatment would result in a significant decrease of the levels of synovial citrullination. 
Our hypothesis was partially confirmed when synovial biopsies obtained following 
intra-articular GC showed significant lower levels of both citrullinated proteins and 
PAD-4 expression. In contrast no such changes were observed for MTX despite clinical 
good response in a majority of the patients.  To investigate a potential direct effect of 
GC on cellular citrullination and PAD expression independent of inflammation we 
further tested the in vitro effect of both GC and MTX in two in vitro assays: synovial 
explants and cultured SFMC. In both systems GC significantly down regulated both 
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expression of citrullinated proteins and PAD-4 expression. One possible explanation of 
the differential effect is a direct NF-ĸB dependent down regulation of PAD-4 
expression by GC but not MTX. The exact molecular mechanisms behind our 
observations as well as the effects of other anti-rheumatic drugs remain to be 
determined.  
 
Disconnection between synovial inflammation and bone destruction in early RA.  
Resident and inflammatory cells in the rheumatoid synovium are a source for local joint 
production of both RANKL and OPG. Expression of these molecules in RA appears to 
be independent of local inflammation. However, all previous studies were conducted in 
established RA where several confounding factors, and especially concomitant anti- 
rheumatic drugs, preclude a clear conclusion. Therefore in (paper 3) we investigated 
expression of RANK, RANKL and OPG in early-untreated RA synovium in relation to 
local synovial inflammation and radiographic evaluation of bone destruction. As 
previously showed, early-untreated RA synovium has architecture indistinguishable of 
established RA, with high number of macrophages and lymphocytes and increased 
vascularity [167]. Also, a relative high RANKL in relation to OPG expression was 
observed accompanied by a general high level of expression of RANK. No correlation 
between synovial expression of RANKL and local synovial inflammation were 
observed. 
 
Targeting synovial inflammation and bone destruction in early untreated RA. 
To further analyze the interplay between inflammation and bone destruction in early-
untreated RA, we followed up newly diagnosed RA patients with a new biopsy after 8 
weeks of MTX treatment. As expected MTX reduced synovial inflammation, as 
evaluated by immunophenotyping of the cells. A reduction of the RANK and 
RANKL/OPG ratio synovial expression was also observed. In accordance with baseline 
data however no correlations were observed between markers of inflammation and 
markers of bone turnover in the biopsies obtained after 8 weeks of MTX treatment. 
Also, changes in the RANKL/OPG ratio were observed both in responders and non-
responders to therapy and mainly limited to those not showing radiographic 
progression. Taken together our biopsy findings give further support to a partial 
uncoupling between inflammation and bone destruction in RA and suggest synovial 
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expression of RANKL and OPG as a potential synovial biomarker for patients that will 
eventually show progression of their erosions despite treatment.  
 
In vitro studies of the molecular mechanisms responsible for inflammation-
independent bone protective effect of MTX.  
To confirm the potential direct effect of MTX on bone metabolism we first investigated 
the effect of in vitro treatment with MTX on SFMC, osteoblast like cells and fibroblasts 
cells. Using either FACS, quantitative PCR, Western blots or ELISA we were able to 
confirm a direct effect of MTX to reduce RANKL expression both at the RNA and 
protein level. Incubation of CD14+ osteoclast precursors with conditioned medium 
from MTX treated osteoblasts reduced pre-osteoclast formation as compared to 
conditioned medium form control treated osteoblasts even in the absence of exogenous 
RANKL. These findings suggest that the MTX induced changes in the RANKL/OPG 
ratio in osteoblasts supernatants might have functional relevance. We were however not 
able to detect many mature osteoclasts, probably due to very low levels of RANKL in 
culture supernatants. We further examined the direct effect of MTX on osteoclast 
differentiation and maturation in a system where enough exogenous RANKL was 
provided.  MTX was able to decrease the number of mature osteoclasts formed from 
CD14+ precursors. This effect was not mediated through induction of apoptosis as 
evaluated by FACS staining with annexin V and 7-AAD (figure 9). 
 
Figure  9. Flow cytometric analysis showing no changes in annexin V (A) and 7AAD (B) gated CD14+ 
cells after MTX treatment. 
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Taken together our in vitro results demonstrate a dual mechanism by which MTX 
might influence bone destruction independent of inflammation: modulation of the 
RANKL expression and direct cellular effect on osteoclast precursors. A schematic 
representation of our view on the effect of MTX on bone metabolism in RA generated 
by our study is given in (figure 10). 
 
     
   
 
Figure 10. Schematic illustration of the current studies on the effects of methotrexate on bone 
metabolism in RA. 
 
 
Hypoxia directly induces RANKL expression in osteoblasts and promotes 
osteoclastogenesis  
To further characterize inflammation-independent mechanisms we investigated in 
(paper 4) if hypoxia a central trait or the rheumatoid joint can modulate bone 
destruction. The inflamed RA synovium is characterized by profound hypoxia as low as 
1-2% oxygen and local expression of both HIF-1α and HIF-2α [135] (figure 11).  
 
Figure 11. Immunohistochemistry showing HIF-1α (A) and HIF-2α (B) expression in RA synovial 
tissue. 
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Exposure of osteoblasts to hypoxia increased RANKL and decreased OPG mRNA 
expression. As a result RANKL cellular protein expression was increased and soluble 
OPG decreased. Transiently transfected siRNA against pVHL under normoxic 
conditions induced increase in RANKL mRNA expression in osteoblast cells 
suggesting that the modulation of RANKL through a HIF mediated mechanism. HIF-
2α but not HIF-1α silencing was able to abolish the effect of hypoxia on RANKL 
expression and ChIP confirmed the direct interaction between HIF-2α with at least one 
hypoxia responsive element (HRE) in the RANKL promoter. This is the first report to 
demonstrate HIF-2α recruitment to the RANKL promoter.  
 
Hypoxia acts synergistically with TNF to promote osteoclastogenesis  
As our original hypothesis was that hypoxia modulates bone destruction independent of 
inflammation we tested the effect of these two conditions on RANKL/OPG pathway 
and osteoclastogenesis either alone or in combination. Simultaneous exposure of 
osteoblasts to hypoxia and TNF resulted in an additive induction of the RANKL/OPG 
ratio as compared to each condition alone.  Culture of PB derived CD14+ cells in the 
presence of conditioned media from osteoblasts exposed to either hypoxia or TNF 
alone without exogenous RANKL added resulted in minimal non significant fold 
increase in the number of both pre-osteoclasts (mono and binuclear TRAP positive 
cells) and mature osteoclasts (multinucleated TRAP positive cells). When same cells 
were cultured in the presence of conditioned medium from osteoblasts exposed to both 
hypoxia and TNF, a significant fold increase in the number of both pre-osteoclasts and 
mature osteoclasts was observed. Taken together our findings suggest that hypoxia 
increases the RANKL/OPG ratio in osteoblasts promoting their osteoclastogenetic 
potential. We further demonstrated that also in the presence of excess exogenous 
RANKL chemical hypoxia (DMOG) acts additively with TNF to promote 
differentiation and maturation of osteoclasts through a direct cellular mechanism. We 
propose that hypoxia acts through dual mechanisms and synergistically with 
inflammation to promote bone destruction in RA (figure 12). 
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Figure 12. Schematic representation of the complex interaction between inflammation and hypoxia 
leading to bone destruction in RA. 
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9. CONCLUSIONS 
The current thesis provides new insights in the molecular mechanisms responsible for 
chronic inflammation and bone destruction in rheumatoid arthritis: 
1. Chronic synovial inflammation is partially dependent on defective T cell 
apoptosis dependent on the soluble cross talk with monocytes. 
2. Synovial citrullination is dependent on local inflammation and targeted by 
local administration of glucocorticoids but not by systemic treatment with 
methotrexate. 
3. Bone destruction is partly uncoupled from synovial inflammation in early RA 
and specific targeted by methotrexate. 
4. Synovial expression of RANKL and OPG is a potential synovial biomarker 
for future radiographic progression.  
5.  Hypoxia induces RANKL expression through a HIF-2α mechanism and 
promotes osteoclastogenesis. 
6. Hypoxia and inflammation additively promotes bone destruction. 
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10. FUTURE PERSPECTIVES 
 
The present thesis aimed to identify and study new molecular pathways contributing to 
chronic inflammation and bone destruction in RA. We started from our previous 
observations showing that defective apoptosis is an important feature of the rheumatoid 
joint that can be reversed by targeting synovial macrophages with TNF antagonists. 
Continuing the same line of research we investigated synovial derived T cells and 
demonstrated that these cells are highly resistant to apoptosis when present in the 
specific inflammatory joint milieu. However upon isolation, T cells were rendered 
sensitive to apoptosis suggesting that soluble factors secreted by monocytes are 
essential in inducing the apoptosis resistance phenotype. It is therefore most probably 
that targeting of monocytes and/or the interaction between monocytes and T cells is 
more effective than selective target of T cells in RA. Also, future directions of research 
opened by this observation are investigation of the interaction between T cell subsets 
and monocytes as well as characterization of the soluble factor(s) responsible for this. 
Once inflammation develops in a certain tissue, local citrullination increases. Our 
hypothesis was that, despite the fact that citrullination is not a RA specific phenomena, 
it still can contribute to local propagation of synovial inflammation. We also thought 
that effective anti-rheumatic treatment would result in a decrease of the levels of 
synovial citrulliantion. To our surprise we observed lower levels of citrullination 
following administration of intra-articular glucocrticoids but not following 
methotrexate treatment suggesting a more fine regulation of synovial citrullination. 
Future extension of our studies to other anti-rheumatic drugs and identification of the 
exact molecular mechanisms responsible for this effect are on the future research 
agenda.    
 
Observations coming from clinical studies have suggested that synovial inflammation 
and bone destruction are at least partly uncoupled. For example, there are patients not 
having any clinical detectable inflammation of the joints that still progress to bone 
destruction and the other way around, patients with ongoing joint inflammation despite 
anti-rheumatic treatment not necessarily progress to bone destruction. We wanted to 
better understand this intriguing and challenging observation, so we focused in the 
second part of the thesis on the interaction between inflammation and bone destruction. 
We were able to demonstrate that markers of increased bone destruction are present in 
the early-untreated RA synovium and their expression is independent of local 
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inflammation but direct modulated by methotrexate treatment. We also identified 
hypoxia as a new molecular mechanism, modulating bone destruction independently 
but additively with inflammation. More in depth studies on the modulation of the 
RANKL pathway and hypoxia in the context of chronic inflammation will contribute to 
better understanding of RA pathogenesis and potential identify new therapeutic targets.  
 
Even though the current thesis has added to the knowledge on disease pathogenesis in 
RA, further research is needed in order for this knowledge to be translated in clinical 
practice and used for the better of RA patients.  
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